The Levels of Anti-SARS-CoV-2 Spike Protein IgG Antibodies Before and After the Third Dose of Vaccination Against COVID-19

Journal of Inflammation Research, Journal Year: 2023, Volume and Issue: Volume 16, P. 145 - 160

Published: Jan. 1, 2023

The COVID-19 pandemic has been going on for almost three years, and so far, many preventive therapeutic strategies have developed. issue of subsequent booster vaccinations is currently being discussed. We aimed to analyze how the third dose vaccination against correlates with dynamics IgG anti-SARS-CoV-2 spike protein antibody levels in a group healthy people.The prospective study included 93 participants before after second vaccination, from whom 4 blood samples were collected at intervals. serum identified using chemiluminescent immunoassay specific receptor-binding domain (RBD) S1 protein. analysis results was performed appropriate statistical methods, considering p <0.05 as statistically significant value.The significantly higher less diverse same follow-up time compared first booster. positively correlated female, healthcare workers, elderly negative history. Furthermore, increase antibodies inversely baseline level vaccination. latest showed that dropped 1.5-fold approx. 10 months but still remained protective level.Booster seem better stimulate immune memory, case borderline induces greatest antibodies. It worth individual parameters patients measuring

Language: Английский

---

Safety, immunogenicity, and breakthrough infections during 1-year follow-up after COVISHIELD™ vaccination among healthcare workers in a teaching institute in North India: A prospective longitudinal study

Journal of Family Medicine and Primary Care, Journal Year: 2025, Volume and Issue: 14(2), P. 655 - 661

Published: Feb. 1, 2025

A prospective longitudinal study was planned to assess immunogenicity, safety, and breakthrough infection rates among health care workers (HCWs) after COVISHIELD™ vaccination in a teaching institute North India. total of 518 HCWs were enrolled at baseline for receiving first dose COVISHIELD™, 429 continued participation second dose, 415 followed up 28 days 405 6 months, 403 1 year from February 2021 November 2022. At each visit prior, 2 ml blood sample collected plasma separated. Anti-SARS-Cov-2 IgG antibodies against spike protein detected by Chemiluminescent Immuno-Assay on the VITROS 3600 platform (Ortho-clinical Diagnostics, NJ, USA). Data analysed (completed all follow-ups), using Statistical Package Social Sciences version 21.0. The mean age participants 35.3 years (SD ± 11.11), males 50.2%. (N = 518), proportion reactive 25% (95% CI, 21-29%), which increased significantly 92% 89-95%) 403), 95% 92-96%) declined 85% 83-93%) six months 403). year, reactivity 89.3% 86-90%; P value < 0.0001). Fever reported 31.2% HCWs, pain injection site (27.6%), malaise (16.4%), headache (3.7%), dizziness (3.7%). Immunogenicity post-COVISHIELD™ doses but inclined dose. safety profile within acceptable limits.

Language: Английский

---

Safety and effectiveness of the booster dose of mRNA COVID-19 vaccines in people with multiple sclerosis: A monocentric experience

Multiple Sclerosis and Related Disorders, Journal Year: 2023, Volume and Issue: 72, P. 104582 - 104582

Published: Feb. 25, 2023

Language: Английский

---

Vaccine-elicited immune pressure and SARS-CoV-2 mutational dynamics in breakthrough infections

Gene Reports, Journal Year: 2024, Volume and Issue: 35, P. 101899 - 101899

Published: Feb. 19, 2024

Language: Английский

---

Salivary Antibody Responses to Two COVID-19 Vaccines following Different Vaccination Regimens

Vaccines, Journal Year: 2023, Volume and Issue: 11(4), P. 744 - 744

Published: March 28, 2023

Background: To date, little is known about the salivary mucosal immune response following different COVID-19 vaccine types or after a booster (3rd) dose of BNT162b2 (BNT) vaccine. Methods: A total 301 saliva samples were collected from vaccinated individuals and arranged into two cohorts: cohort 1 (n = 145), who had received doses against SARS-CoV-2; 2 156), BNT Cohorts sub-stratified three groups based on first second (homologous BNT/BNT, homologous ChAdOx1/ChAdOx1, heterologous BNT/ChAdOx1vaccinations). Salivary immunoglobulin G (IgG) to SARS-CoV-2 spike glycoprotein was measured by ELISA, clinical demographic data hospital records questionnaires. Results: IgG antibody responses vaccines, whether heterogeneous vaccination regimens, showed similar levels in cohorts 2. Compiling all significant, albeit weak, negative correlations between time (r −0.2, p 0.03; r −0.27, 0.003, respectively). In 2, durability significantly dropped 3 months compared <1 month 1–3 groups. Conclusions: Different regimens elicit anti-SARS-CoV-2 with modest waning over time. Boosting did not produce an evident increase whereby recovered subjects show higher than naive, post-vaccination subjects. The ChAdOx1/ChAdOx1 regimen better correlation durability. These findings highlight importance developing oral intra-nasal vaccines induce stronger immunity.

Language: Английский

---

The Impact of Body Mass Index on the Antibody Titer after Astra Zeneca Vaccination at UTA’45 Vaccine Center

Research Journal of Pharmacy and Technology, Journal Year: 2023, Volume and Issue: unknown, P. 2689 - 2693

Published: June 26, 2023

Background: AstraZeneca is the viral vector vaccine. This vaccine has a more advanced method that uses modified virus to trigger antibodies fight Covid-19 virus. Objective: To evaluate impact of Body Mass Index on Antibody Titer after Vaccination atUTA'45 Vaccine Center. Method: Cross-sectional prospective was used in this study with convenience sampling design. Only participants who signed informed consent were included study. Results: The results P-value comparison Gender and BMI are 0.36 which indicates correlation between Gender, also age (the P-Value 0.57) plays an important role these factors. one factors influence development vaccination. titer 2 significantly affected by BMI, antibody very significant ( 0,000). Conclusion: Based study, it found there Age, However, Age not significant, presence can still affect Titers. In addition, be concluded (post-vaccination titer) person's BMI. shown from 0.000.

Language: Английский

---

Kinetics of dried blood spot-measured anti-SARS-CoV2 Spike IgG in mRNA-vaccinated healthcare workers

Frontiers in Microbiology, Journal Year: 2023, Volume and Issue: 14

Published: March 1, 2023

Introduction One of the major criticisms facing research community during SARS-CoV2 pandemic was lack large-scale, longitudinal data on efficacy mRNA vaccines. Currently, even if COVID-19 antiviral treatments have been authorized by European Medicine Agency, prevention through approved specific vaccines is best approach available in order to contain ongoing pandemic. Objectives Here, we studied antibody kinetic over a one-year period from vaccination with Pfizer-BioNTech (Pfizer) and subsequent boosting either BioNTech or Moderna (Spikevax) large cohort 8,071 healthcare workers (HCW). We also described impact infection same period. Methods assessed anti SARS - CoV2 Spike IgG high throughput dried blood spot (DBS) collection method GSP®/DELFIA® Anti-SARS-CoV2 assay (PerkinElmer®). Results Our support existing models showing that elicits strong initial antibodies responses decline time but are transitorily increased administering vaccine booster. showed using heterologous vaccine/booster combinations stronger response elicited than utilizing booster manufacturer. Furthermore, considering occurrence proximity scheduled administration, confirmed dose did not contribute significantly elicit higher responses. Conclusion DBS sampling our population HCWs fundamental collect number specimens clarify effective vaccine-induced role both boosters modulating

Language: Английский

---

RBD-Adjuvanted Preparation: Evaluation of IgG and IgM Antibodies for One Year and Cross-Reactivity with Omicron Variant in Mice

Published: Sept. 25, 2023

This study continued the analysis of immunization with receptor binding domain (RBD) associated adjuvants Dimethyldioctadecylammonium bromide (DDA) and Saponin (Sap) (RBD+DDA/Sap) or Aluminum hydroxide (AH) outer membrane vesicles (OMVs) Neisseria meningitidis (RBD+AH/OMV); from adult to old age assessed maternal-fetal transference antibodies. Outbred Swiss mice were immunized 2 intramuscular (IM) doses antigenic preparations RBD+DDA/Sap, RBD+AH/OMV RBD alone. The humoral immune response was evaluated using ELISA, avidity-ELISA, Immunoblotting a Omicron-surrogate-neutralization assay (BA.1), while cellular analyzed by ELISpot. Our previous work studied IgG response; here, we verified that IgM levels higher right after doses, but, as IgG, it persisted until 368 days immunization. avidity increased low intermediate-to-high booster dose. RBD+DDA/Sap presented neutralizing indexes against Omicron at 47 176, showed neutralization on 21, 176. Cellular response, measured 465 immunization, revealed IFN-Y IL-4 secretion. offspring had detectable antibodies, which decreased around 45 birth, last point analyzed. results suggested DDA/Sap is promising adjuvant mixture enhance SARS-CoV-2, improving antibodies; cross-reactivity variant; maintenance antibodies for long period.

Language: Английский

---

Robust memory humoral immune response to SARS-CoV-2 in the tonsils of adults and children

Frontiers in Immunology, Journal Year: 2023, Volume and Issue: 14

Published: Dec. 11, 2023

Background Adaptive humoral immunity against SARS-CoV-2 has mainly been evaluated in peripheral blood. Human secondary lymphoid tissues (such as tonsils) contain large numbers of plasma cells that secrete immunoglobulins at mucosal sites. Yet, the role memory induced by vaccines or natural infection and its variants is not fully understood. Methods Tonsillar mononuclear (TMNCs) from adults (n=10) children (n=11) were isolated stimulated using positive nasal swabs. We used endpoint enzyme-linked immunosorbent assays (ELISAs) for measurement anti-S1, -RBD, -N IgG antibody levels a pseudovirus microneutralization assay to assess neutralizing antibodies (nAbs) paired serum supernatants TMNCs. Results Strong systemic response previously infected vaccinated was observed accordance with reported history participants. Interestingly, we found significant increase anti-RBD (305 834 folds) anti-S1 (475 443 TMNCs children, respectively, compared unstimulated cells. Consistently, secreted higher nAbs ancestral Wuhan strain Omicron BA.1 variant several folds. This seen all participants including no known infection, suggesting these might have exposed asymptomatic cases necessarily could be detected antibodies. Furthermore, nAb both strains significantly correlated (r=0.8788; p = 0.0008) (r 0.7521; 0.0076), they strongly S1 RBD-specific Conclusion Our results provide evidence persistent tonsils and/or recent old upon re-exposure. They also highlight importance targeting sites help control primary prevent potential breakthrough infections.

Language: Английский

---

Comprehensive Evaluation of COVID-19 Vaccines Antibody Response Among Healthcare Professionals: A Multi-Center Study in Iran

Archives of Clinical Infectious Diseases, Journal Year: 2024, Volume and Issue: 19(1)

Published: Feb. 5, 2024

Background: The coronavirus disease 2019 (COVID-19) vaccines are very good at protecting individuals from serious illness, needing hospital care, and dying different strains of the virus. However, might not completely prevent catching spreading virus, this depend on some personal factors. Objectives: To find out immune response COVID-19 vaccines, cross-sectional study conducted within June 2021 to May 2023 assessed types vaccine antibody responses among healthcare professionals their associations with demographic factors comorbidity risk Methods: This descriptive-analytical was recruited Sina, Imam Khomeini Complex, 501 AJA, Baqiayatallah, Firoozgar hospitals in Tehran, Iran. whose investigated Sinopharm® (China), AstraZeneca® (United Kingdom), Sputnik® (Russia), Covaxin® (India). Anti-spike, anti-receptor-binding domain (RBD), anti-neutralizing immunoglobulin G (IgG) were evaluated by commercial kits according instructions. Results: involved 1 029 workers who over 18 years old. average age 41.48 ± 9.9 years, 602 (58.5%) them male. they received Sputnik V (392 or 38.16%), AstraZeneca (335 32.61%), Baharat (45 4.3%), Sinopharm (255 24.82%). Covaxin increased both anti-RBD IgG Ab levels; however, only latter. least effective. Gender diabetes influenced levels, but did not. Conclusions: revealed substantial effectiveness generating robust professionals. All four types, Sinopharm, AstraZeneca, Sputnik, Covaxin, elicited significant 70% participants, highlighting crucial role vaccination building defense against COVID-19.

Language: Английский

---